SCHEMBL4126631

SCHEMBL4126631

CN(Cc1cc(-c2cccnc2F)c(S(=O)(=O)c2ccc(Cl)nc2)s1)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.34
HSD17B1 P14061 3/20 0.34
HSD17B2 P37059 3/20 0.34
CYP2C19 P33261 1/20 0.34
PTPN22 Q9Y2R2 1/20 0.34
MAPT P10636 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
IDH2 P48735 1/20 0.32
NAMPT P43490 1/20 0.32
LMNA P02545 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4117741 0.88 LIPG (0.31) IDH2
SCHEMBL3803075 0.88 ALDH1A1 (0.33) ALDH1A1MEN1KMT2ATDP1L3MBTL1
SCHEMBL3782033 0.88 NAMPT (0.37) ALDH1A1NAMPTLMNA
SCHEMBL4125901 0.88 NAMPT (0.35) ALDH1A1GAAIDH2NAMPT
SCHEMBL3803078 0.87 ALDH1A1 (0.36) ALDH1A1MEN1KMT2ATDP1L3MBTL1
SCHEMBL4117657 0.86 GPBAR1 (0.33) IDH2NAMPT
SCHEMBL3773531 0.84 IDH2 (0.34) ALDH1A1IDH2NAMPT
SCHEMBL3649326 0.84 HTR6 (0.39) ALDH1A1
SCHEMBL3803076 0.84 ALDH1A1 (0.34) ALDH1A1MEN1KMT2ATDP1L3MBTL1
Hydrochloric Acid SCHEMBL3644779 0.83 KAT6A (0.32) ALDH1A1MEN1KMT2AHSD17B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190822-B1 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-12-31 EP disclosed
US-20090156642-A1 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156642-A1 5-Membered heterocyclic compound CEL, PGA5, COG5 ALDH1A1 1497/4885MEN1 1910/4885KMT2A 4776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.